|Articles|February 19, 2010

2010 Media Kit

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

FDA approves leniolisib for children aged 4 to 11 with APDS

ByBenjamin P. Saylor

September 11th 2026

FAQ: What's new in COVID-19, RSV, and flu guidance? | Image Credit: © AntonioDiaz - stock.adobe.com

FAQ: What's new in COVID-19, RSV, and flu guidance?

ByContemporary Pediatrics Staff

September 11th 2026

Contemporary Pediatrics week in review: September 7-11, 2026

Contemporary Pediatrics week in review: September 7-11, 2026

ByContemporary Pediatrics Staff

September 11th 2026

From index of suspicion to managing survivorship: A primary care toolkit for childhood cancer | Image Credit: © Alex Shared/peopleimages.com - stock.adobe.com.

From index of suspicion to managing survivorship: A primary care toolkit for childhood cancer

ByLianna J. Marks, MD,Sharon M. Castellino, MD, MSc

September 10th 2026

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents

ByCharles Vega, MD, FAAFP

September 10th 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

FAQ: What's new in COVID-19, RSV, and flu guidance?

FDA approves leniolisib for children aged 4 to 11 with APDS

A teenaged girl with flat-topped papules

From index of suspicion to managing survivorship: A primary care toolkit for childhood cancer

XOCOVA offers new post-exposure COVID-19 prevention option for adolescents